Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us
Pipeline News and Updates
Picture

Update for May 4, 2021

5/4/2021

 
Regulatory Update
 
The FDA accepted the NDA for bardoxolone methyl for the treatment of chronic kidney disease caused by Alport syndrome and set a PDUFA date for 2/25/2022.
 
In April 2021, Lilly discontinued development of mirikizumab for the treatment of psoriasis. Lilly has ongoing trials evaluating mirikizumab in the treatment of ulcerative colitis and Crohn's disease.
 
Beginning in mid-July, Biogen will allow access through a compassionate use program for tofersen to treat rapidly progressing ALS patients with SOD1 mutations. In the fall of 2021, if tofersen is found to be safe and effective in a Phase III trial, an Early Access Program will be initiated for a broader range of ALS patients with SOD1 mutations.
 
Enzyvant resubmitted a BLA for RVT-802 for the treatment of pediatric patients with congenital athymia.
 
The FDA delayed review of pegunigalsidase alfa until a site inspection could be completed at Protalix's manufacturing facility in Carmiel, Israel.
 
The FDA rejected the NDA for tralokinumab and requested additional information on a device used in the delivery of the drug. The EMA’s CHMP recommended approval of the MAA for tralokinumab for the treatment of moderate-to-severe atopic dermatitis.
 
The FDA has extended the PDUFA date for BioMarin's vosoritide by three months to allow additional time to review recently submitted results from a two-year Phase III extension study.
 
Announced Research Updates
 
Aldeyra announced that in the 210 minute 95 patient, Phase III, INVIGORATE trial, treatment with reproxalap 0.25% ophthalmic solution reduced the subject-reported ocular itching score compared to placebo in patients with seasonal allergic conjunctivitis. 
 
Revance announced that in an 84-week, analysis of 568 patients from the Phase III, SAKURA 3 trial, four-weeks after the first injection of daxibotulinumtoxinA, up to 57.9% of patients perceived no static Glabellar lines (GL). After a second injection 68.7% reported no GL and 71.5% after the third treatment in patients with mild and moderate static Glabellar lines. Similar improvements were observed by investigators. Patients with severe static GL also achieved no static GL with a third cycle of daxibotulinumtoxinA.
 
Pharnext announced interim results after 54-months from a long-term extension of the Phase III study PLEO-CMT trial. In the PLEO-CMT-FU extension trial, treatment with PXT3003 continued to demonstrate an improvement in the ONLS compared to placebo in patients with mild to moderate Charcot-Marie-Tooth Type 1A Disease.
 
Brickell announced that 190 patients completed the 52-week, 300 patient, Phase III ARGYLE trial, where treatment with sofpironium bromide improved the proprietary patient-reported Hyperhidrosis Disease Severity Measure-Axillary (HDSM-Ax) scale by one-point in 86.1% of patients that received a 5% gel and 85.8% with the 15% gel in patients with primary axillary hyperhidrosis. A two-point improvement in the HDSM-Ax score was achieved by 69.4% of 5% patients and 61.9% of 15% patients. Mostly mild or moderate adverse events were experienced by 22.5% of patients treated with sofpironium bromide gel 5% and 50.8% with 15%. Most adverse events were transient, so treatment discontinuations decreased over time.
 
AB Science announced that in a 580 patient, Phase IIb/III trial, treatment with masitinib plus docetaxel and prednisone improved progression-free survival compared to docetaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer.
 
Published Research Updates
 
In the 36-week, 1,751 patient, Phase III, PRO2TECT Correction trial, vadadustat was non-inferior to darbepoetin in the change in hemoglobin, 1.43 vs 1.38 for a 0.05 g/dL difference, in CKD patients with anemia not on dialysis, who had not received previous ESA treatment. In the 36-week, 1,725 patient, Phase III, PRO2TECT Conversion trial, vadadustat was non-inferior to darbepoetin in the change in hemoglobin, 0.41 vs 0.42 for a 0.01 g/dL difference, in CKD patients with anemia not on dialysis, treated with an ESA. The incidence of MACE (composite endpoint of all-cause mortality, non-fatal myocardial infarction, or non-fatal stroke) with vadadustat compared to darbepoetin in the two PRO2TECT trials involving 3,471 CKD patients with anemia not on dialysis, found that 22% of vadadustat patients experienced a MACE event compared to 19.9% with darbepoetin for a hazard ratio of 1.17.
 
In the 36-week, 369 patient, Phase III, INNO2VATE Correction/Conversion trial, vadadustat was non-inferior to darbepoetin in the change in hemoglobin, 1.26 vs 1.58 for a 0.31 g/dL difference, in patients receiving chronic dialysis for end-stage renal disease. In the 36-week, 3,554 patient, Phase III, INNO2VATE Conversion trial, vadadustat was non-inferior to darbepoetin in the change in hemoglobin, 0.19 vs 0.36 for a 0.17 g/dL difference, in patients receiving chronic dialysis for end-stage renal disease. The incidence of MACE (composite endpoint of all-cause mortality, non-fatal myocardial infarction, or non-fatal stroke) in the two INNO2VATE trials involving 3,902 patients with anemia and dialysis-dependent chronic kidney disease, was 18.2% with vadadustat, which was non-inferior to 19.3% with darbepoetin for a hazard ratio of 0.96.
 
In the 260 patient, Phase II, INTELLANCE-2, open label trial treatment with depatuxizumab and temozolomide did not improve the overall survival rate compared totemozolomide alone in patients with EGFR-amplified glioblastoma. 
 
In a 4-week, 416 patient, Phase IIb, dose ranging trial, ensifentrine plus tiotropium increased FEV1 compared to tiotropium alone (ensifentrine dose-dependent increase of 77.5 mL to 124.2 mL) in patients with chronic obstructive pulmonary disease.

Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    March 2023
    February 2023
    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.